The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Investigation, Treatment, and Monitoring of Late‐Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations
Open accessAbstract
Demographic data clearly demonstrate that the percentage of the population in the older age group is increasing. Androgen deficiency in the aging male has become a topic of increasing interest and debate throughout the world. Cross-sectional and longitudinal data indicate that testosterone falls progressively with age and that a significant percentage of men over the age of 60 years have serum testosterone levels that are below the lower limits of young adult (age, 20–30 years) men (Gray et al, 1991; Harman et al, 2001; Araujo et al, 2007; Wu et al, 2008). The principal questions raised by these observations are whether older hypogonadal men will benefit from testosterone treatment and what will be the risks associated with such intervention. The past decade has brought evidence of benefit of androgen treatment of hypogonadal men on multiple target organs, and recent studies show short-term beneficial effects of testosterone in older men that are similar to those in younger men. This has been comprehensively reviewed and summarized by the Institute of Medicine in Testosterone and Aging: Clinical Research Directions (Liverman and Blazer, 2004). Long-term data on the effects of testosterone treatment in the older population are limited mainly to effects on body composition and bone mass (Snyder et al, 1999a,b; Amory et al, 2004; Isidori et al, 2005a,b; Page et al, 2005). Key questions of the effects of testosterone on patient reported outcomes and functional benefits that may retard physical or mental frailty of the elderly or improve the quality of life are not yet available. Specific risk data on the prostate and cardiovascular systems are needed. Recent guidelines for the testosterone treatment of younger hypogonadal men are available from professional societies (AACE Hypogonadism Task Force, 2002; The Practice Committee of the American Society for Reproductive Medicine, 2004; Bhasin et al, 2006). Recommendations on the diagnosis, treatment, and monitoring of late-onset hypogonadism was published by the International Society for the Study of Aging Male (ISSAM) in 2002 (Morales and Lunenfeld, 2002). In 2005, a writing committee formed by the International Society of Andrology (ISA), the ISSAM, and the European Association of Urology (EAU) prepared a set of recommendations specifically on the “investigation, treatment, and monitoring of late onset hypogonadism.” In order to reach a large audience, these recommendations were published in the International Journal of Andrology, the Journal of Andrology, the Aging Male, and European Urology (Nieschlag et al, 2005a,b,c, 2006). In view of the growing interest from practitioners on the treatment of older men with testosterone, the ISA, ISSAM, EAU, European Academy of Andrology (EAA), and American Society of Andrology (ASA) convened meetings of the writing group with expert representatives from each of the societies. The writing group membership from 2005 was expanded to include additional urologists. Members of the writing group met in Berlin in 2007, Toronto in 2007, and Tampa in 2008 to revise these recommendations. There was no corporate funding or support for the development of these recommendations. The revised recommendations are supported by a selection of appropriate references and categorized by the level of evidence and grade of recommendation according to the US Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research (1992:115–127; Table). To ensure broad outreach to multidisciplinary audiences, these recommendations are published in the European Journal of Endocrinology, European Urology, the International Journal of Andrology, the International Journal of Impotence Research, the Journal of Andrology, and The Aging Male simultaneously. Late-onset hypogonadism (LOH, also referred to as age-associated testosterone deficiency syndrome [TDS]) is a clinical and biochemical syndrome associated with advancing age and characterized by symptoms and a deficiency in serum testosterone levels (below the young healthy adult male reference range; Morales et al, 2006; Nieschlag et al, 2005a,b,c, 2006). This condition may result in significant detriment in the quality of life and adversely affect the function of multiple organ systems. At present, the diagnosis of treatable hypogonadism requires the presence of symptoms and signs suggestive of testosterone deficiency (level 3, grade A; Bhasin et al, 2006; Nieschlag et al, 2005a,b,c, 2006). The symptom most associated with hypogonadism is low libido (level 3, grade A; Schiavi et al, 1991; Travison et al, 2006). Other manifestations of hypogonadism include: erectile dysfunction (ED), decreased muscle mass and strength, increased body fat, decreased bone mineral density and osteoporosis, decreased vitality, and depressed mood. None of these symptoms are specific to the low-androgen state, but may raise suspicion of testosterone deficiency. One or more of these symptoms m
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Self-citationLongitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 4×
“However, a free testosterone level below 225 pmol/l (65 pg/ml)canprovidesupportiveevidencefor testosterone treatment(37, 38 , 42)(Level 3, Grade C). Threshold values for bioavailable testosterone depend on the method used and are not generally available (38).”
BackgroundMethodInfluentialGRAY, A., FELDMAN, H. A., MCKINLAY, J. B., & LONGCOPE, C. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-5-1016 · Cited by 1,118
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Self-citationWu, F. C. W., Tajar, A., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F., Forti, G., Giwercman, A., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1972 · Cited by 939
Self-citationAssessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial
Thompson, I. M., Ankerst, D. P., Chi, C., Goodman, P. J., Tangen, C. M., Lucia, M. S., Feng, Z., Parnes, H. L., & Coltman, C. A. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj131 · Cited by 938
Self-citationLaaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssönen, K., Tuomainen, T.-P., Valkonen, V.-P., Salonen, R., & Salonen, J. T. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1036 · Cited by 920
Kapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02166 · Cited by 791
Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies
Hormones, E. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djm323 · Cited by 786
Cited by
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544
Self-citationGuidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation
Hatzimouratidis, K., Amar, E., Eardley, I., Giuliano, F., Hatzichristou, D., Montorsi, F., Vardi, Y., & Wespes, E. (2010) · European Urology · doi:10.1016/j.eururo.2010.02.020 · Cited by 1,223
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Self-citationInvestigation, treatment and monitoring of late-onset hypogonadism in males
Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J.-J., Lunenfeld, B., Morales, A., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0601 · Cited by 867
Self-citationAssociation of Specific Symptoms and Metabolic Risks with Serum Testosterone in Older Men
Zitzmann, M., Faber, S., & Nieschlag, E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0401 · Cited by 552
Self-citation
Metadata
- Authors
- Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J. ‐., Lunenfeld, B., Morales, A., Morley, J. E., Schulman, C., Thompson, I. M., Weidner, W., & Wu, F. C. W.
- Venue
- Journal of Andrology
- Publisher
- Wiley
- Published
- 2009-01-02
- Volume
- 30
- Issue
- 1
- Pages
- 1-9
- ISSN
- 0196-3635 (ISSN-L)
- 1939-4640
- OpenAlex
- W2112869229
- Cited by
- 445
- References
- 89
- FWCI
- 24.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Investigation, Treatment, and Monitoring of Late‐Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations. https://app.cochat.ai/papers/10.2164/jandrol.108.006486
- The paper
- Wang, C., Nieschlag, E., Swerdloff, R., Behre, H. M., Hellstrom, W. J., Gooren, L. J., Kaufman, J. M., Legros, J. ‐., Lunenfeld, B., Morales, A., Morley, J. E., Schulman, C., Thompson, I. M., Weidner, W., & Wu, F. C. W. (2009). Investigation, Treatment, and Monitoring of Late‐Onset Hypogonadism in Males: ISA, ISSAM, EAU, EAA, and ASA Recommendations. Journal of Andrology. https://doi.org/10.2164/jandrol.108.006486
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.